• Bulletin of the Korean Chemical Society
• /
• 제33권2호
• /
• pp.433-442
• /
• 2012

The promise of stem cell therapy for various clinical applications seems getting realistic. An increasing number of researchers, from virtually every discipline of natural sciences, are flocking into this new world. Only ten years ago, gene therapy was the medicine for the 21st century. The possibility was endless. Although the science itself underlying gene therapy was very young, the field was exploding under the optimism that this new medicine would revolutionize both the basic and clinical sciences. For many reasons, the initial target was cancer. Here, we will focus on the results of cancer gene therapy clinical trials using liposome or nonviral gene carrier, hoping that the lesson from here will be a guideline for the new generation of cell-based therapies.

• 대한임상검사과학회지
• /
• 제39권1호
• /
• pp.31-36
• /
• 2007

The purpose of the clinically reportable range (CRR) in clinical chemistry is to estimate linearity in working range. The reportable range includes all results that may be reliably reported, and embraces two types of ranges: the analytical measurement range (AMR) is the range of analyte values that a method can directly measure on the specimen without any dilution, concentration, or other pretreatment not part of the usual assay process. CAP and JCAHO require linearity on analyzers every six months. The clinically reportable range is the range of analyte values that a method can measure, allowing for specimen dilution, concentration, or other pretreatment used to extend the direct analytical measurement range. The AMR cannot exceed the manufacturer's limits. Establishing AMR is easily accomplished with Calibration Verification Assessment and experimental Linearity. For example: The manufacturer states that the limits of the AST on their instrument are 0-1100. The lowest level that could be verified is 2. The upper level is 1241. The verified AMR of the instrument is 2-1241. The lower limit of the range is 2, because that is the lowest level that could be verified by the laboratory. The laboratory could not use the manufacturer's lower limit of 2 because they have not proven that the instrument values below 2 are valid. The upper limit of the range is 1241, because although the lab has shown that the instrument is linear to 1241, the manufacturer does not make that claim. The laboratory needs to demonstrate the accuracy and precision of the analyzer, as well the validation of the patient AMR. Linearity requirements have been eliminated from the CLIA regulations and from the CAP inspection criteria, however, many inspectors continue to feel that linearity studies are a part of good lab practice and should be encouraged. If a lab chooses to continue linearity studies, these studies must fully comply with the calibration/calibration verification requirements of CLIA and/or CAP. The results of lower limit and upper limit of clinically reportable range were total protein (2.1 - 79.9), albumin (1.3 - 39), total bilirubin (0.2 - 106.2), alkaline phosphatase (13 - 6928.2), aspartate aminotransferase (24 - 7446), alanine aminotransferase (13 - 6724.2), gamma glutamyl transpeptidase (16.64 - 9904.2), creatine kinase (15.26 - 4723.8), lactate dehydrogenase (127.66 - 13231.8), creatinine (0.4 - 129.6), blood urea nitrogen (8.67 - 925.8), uric acid (1.6 - 151.2), total cholesterol (48.52 - 3162), triglycerides (36.91 - 3367.8), glucose (31 - 4218), amylase (21 - 6694.2), calcium (3.1 - 118.2), inorganic phosphorus (1.11 - 108), HDL (11.74 - 666), NA (58.3 - 1800), K (1.0 - 69.6), CL (38 - 1230).

• 대한임상검사과학회지
• /
• 제38권3호
• /
• pp.184-188
• /
• 2006

The purpose of the recovery experiment in clinical chemistry is performed to estimate proportional systematic error. We must know all measurements have some error margin in measuring analytical performance. Proportional systematic error is the type of error whose magnitude increases as the concentration of analyte increases. This error is often caused by a substance in the sample matrix that reacts with the sought for analyte and therefore competes with the analytical reagent. Recovery experiments, therefore, are used rather selectively and do not have a high priority when another analytical method is available for comparison purposes. They may still be useful to help understand the nature of any bias revealed in the comparison of kit experiments. Recovery should be expressed as a percentage because the experimental objective is to estimate proportional systematic error, which is a percentage type of error. Good recovery is 100.0%. The difference between 100 and the observed recovery(in percent) is the proportional systematic error. We calculated the amount of analyte added by multiplying the concentration of the analyte added solution by the dilution factor(mL standard)/(mL standard + mL specimen) and took the difference between the sample with addition and the sample with dilution. When making judgments on method performance, the observed that the errors should be compared to the defined allowable error. The average recovery needs to be converted to proportional error(100%/Recovery) and then compared to an analytical quality requirement expressed in percent. The results of recovery experiments were total protein(101.4%), albumin(97.4%), total bilirubin(104%), alkaline phosphatase(89.1%), aspartate aminotransferase(102.8), alanine aminotransferase(103.2), gamma glutamyl transpeptidase(97.6%), creatine kinase(105.4%), lactate dehydrogenase(95.9%), creatinine(103.1%), blood urea nitrogen(102.9%), uric acid(106.4%), total cholesterol(108.5), triglycerides(89.6%), glucose(93%), amylase(109.8), calcium(102.8), inorganic phosphorus(106.3%). We then compared the observed error to the amount of error allowable for the test. There were no items beyond the CLIA criterion for acceptable performance.

• Bulletin of the Korean Chemical Society
• /
• 제25권8호
• /
• pp.1247-1250
• /
• 2004

• 한국수의병리학회지
• /
• 제1권1호
• /
• pp.46-52
• /
• 1997

The hematology and clinical chemistry data based on the well defined normal data are essential in the safety assessment. It is important that normal values of cliniclal pathology parameters would be optimized to be accurate. So the purpose of this experiment was to compare the ranges of normal data in hematology value and serum chemistry between both sexes of F344 and Wistar rats at 5, 10, 20, 40 and 90 weeks. of age. The neutrophils eosinophils and monocytes increased with age in male Wistar rats. And serum total bilirubin and potassium were highest and alkaline phosphatase was lowest at 90 weeks in Wistar rats. As compared with Wistar rat the serum aspartate aminotransferase of F344 rats increased with age in both sexes but inorganic phosphorus decreased with age. The serum alkaline phosphatase decreased with age and potassium was highest at 90weeks. These normal data would be useful in improving the accuracy of clinical pathology value in the safety assessment.

• 한국임상수의학회지
• /
• 제30권1호
• /
• pp.75-79
• /
• 2013

Laminitis is a common horse disease that causes pain and disability. One of the major causes of laminitis is carbohydrate overload, which leads to the overgrowth of gram-positive bacteria and subsequent toxemia. This study was performed to establish an experimental model of acute phase laminitis. A horse was fed with a bolus dose of oligofructose, examined for clinical signs and blood parameters, and euthanized for necropsy and histopathology. After administration, the horse exhibited clinical signs including watery feces, inappetence, severe lameness, pyrexia and tachycardia. Complete blood count showed increased hematocrit, lymphocytosis and neutropenia. Serum chemistry revealed hyperglycemia, hyperproteinemia, high level of glutamic oxalate transaminase, creatinine, uric acid and mild hyponatremia. Histologically, the lamina tissue was edematous with mild infiltration of inflammatory cells. These findings indicate that oligofructose-induced laminitis in horse is an appropriate model for studying pathogenesis of acute phase laminitis.

• 한국건강관리협회지
• /
• 제4권1호
• /
• pp.60-67
• /
• 2006

Purpose : Asian Quality Assurance Survey program(AQuAS) is and activity of Asian Network for Clinical Laboratory Standardization and Harmonization(ANCLS) which had begun her first colloquium in 1999 in Jakarta, Indonesia by laboratory physicians led by Professors Noriyuki Tatsumi and Yoshinori Funahara with themes of standardization and harmonization of clinical laboratories in Asia. Methods : AQuAS had begun its first survey in July. 2001 and done November and March, three times per year in the fields of Chemistry, Hematology. Coagulation and Urinalysis. As of June 2006 the 15th survey have been completed. Korean Association of Health Promotion(KAHP) had participated in it since July, 2004 in the fields of chemistry, hematology and urinalysis.ゝ⨀

• 대한심미치과학회지
• /
• 제23권2호
• /
• pp.58-69
• /
• 2014

In case of esthetic restorative procedure with zirconia restoration, we have to use resin cement because of not only just for retention but also esthetic reason. In such a clinical situation, we have to consider two bonding interfaces, one is tooth surface to resin cement and the other is zirconia surface to resin cement. There is well established bonding protocol between tooth surface to resin cement, but bonding protocol of zirconia surface to resin cement is still controversial. In scientific point of view, there are two mechanism for bonding of zirconia restoration.. One is mechanical retention and the other is chemical adhesion. However, we have three different options for bonding of zirconia restoration in clinical situation; 1) Tribo-chemical coating with silica and silane coupling agent 2) Zirconia primer with phosphate chemistry 3) Self-adhesive resin cement with phosphate chemistry.

• Bulletin of the Korean Chemical Society
• /
• 제30권4호
• /
• pp.927-930
• /
• 2009

• Natural Product Sciences
• /
• 제4권1호
• /
• pp.1-8
• /
• 1998

An overview of the history of the evolution of health practice in the United States. The development of selected laws regulating the marketing of botanical commodities and recent efforts to standardize them. Some consideration is given to the clinical testing and clinical use of botanical commodities.